David Avigan, MD
Beth Israel Deaconess Medical Center / Dana Farber-Harvard Cancer Center
Clinical Title: Blockade of PD-1 in Conjunction with the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation
Description: Custom vaccines that stimulate the immune systems of cancer patients are being used with success by investigators. However, vaccines have their own limitations in activating the patient’s T cells to target and eradicate deadly tumor cells. In an effort to give myeloma patients another weapon against cancer, Dr. Avigan and his team at Beth Israel Deaconess Medical Center and the Dana Farber/Harvard Cancer Center, have begun new research to provide patients with an extra cancer-fighting antibody that amplifies the body’s immune response in its quest for a disease-free state. This research potentially creates a new option for maximizing the effectiveness of healthy T cells that act like soldiers destroying the cancer. This study is important because it is one of the first times the antibody will be used in this way, potentially creating a new option for maximizing the effectiveness of healthy T cells that act like soldiers destroying the cancer. This strategy holds promise myeloma and for many cancers including solid tumors and other blood cancers.
In an effort to give myeloma patients another weapon against cancer, Dr. Avigan and his team have begun new research to provide patients with an extra cancer-fighting antibody that amplifies the body’s immune response in its quest for a disease-free state.
The purpose of this research study is to determine the safety of CT-011 alone, as well as the combination of the Dendritic cell fusion vaccine and CT-011, after autologous stem cell transplantation (ASCT). The trial is also trying to find out what effect the combination has on the disease, including if it is more successful in preventing or delaying the disease from coming back, compared to treatment with autologous transplantation alone. ASCT is a standard therapy for multiple myeloma that is often successful in significantly decreasing the amount of cancer in the body. CT-011 is an investigational monoclonal antibody. Monoclonal antibodies are a type of drug given by infusion into a vein and are known to target specific cells (in this case, cells in the immune system). The dendritic cell fusion vaccine is an investigational agent that tries to help the immune system to recognize and fight against cancer cells. Unlike a standard vaccine that is used to prevent infections, cancer vaccines are being studied to see if they can fight cancers that are already in the body.
Status: Active Trial
Accepting Patients? Yes
NIH Clinical Trial Link: http://clinicaltrials.gov/show/NCT01067287« Back to Funded Clinical Trials
One American dies every 57 seconds from cancer.
These are loved ones, not statistics.
Demanding it all!
Funding innovative cancer research for
Treatments. Cures. Life.